Artificial Intelligence

A new cell-free therapy for the fatal lung disease IPF is heading to clinical trials, thanks to a key manufacturing partnership. Here's what it means.

Chinese insurtech Huize is cutting back on financial reports to focus on strategy, but its latest data shows a complex picture of soaring premiums and slowing new user growth.

American Express has locked in its 2026 earnings call schedule. Here’s what investors and analysts will be watching for amid shifting economic signals.

Ursa Space Systems has been selected for the MDA's $151B SHIELD contract, signaling a new era of AI-driven satellite intelligence for homeland defense.

Ekinops' new high-density module simplifies complex networks, cuts costs, and paves the way for terabit-speed connectivity in the 5G and AI era.

Michelin and Sonatus are set to reveal a digital tire twin at CES 2026, using AI to predict wear and tear and promising a future of safer, more efficient driving.

Securities processors have filed a plan to extend trading to nearly 24 hours a day, a move set to transform Wall Street but posing huge tech hurdles.

Bangkok's Glow Digital named top SEO agency for its unique blend of PR, content, and future-proof AI strategies, setting a new standard in a competitive market.

With a star-studded 2026 lineup and rapid global expansion, Barco's advanced HDR Lightsteering technology is poised to become the new premium cinema standard.

Mirum raises over a quarter-billion dollars to acquire Bluejay Therapeutics, targeting a high-potential liver disease drug and signaling major growth.

A new line of vibration and bone-conduction sensors from Upbeat Technology aims to revolutionize voice AI, wearables, and drones with crystal-clear audio.

A cancer research firm is betting its future on Zcash, recruiting the crypto's top minds. Is this the start of institutional adoption for privacy coins?

Alvotech and Teva's settlement with Regeneron for an Eylea biosimilar paves the way for a 2026 launch, promising increased competition and lower costs.

The VCT posts a marginal loss but shows second-half recovery, while navigating strategic exits and facing a pivotal shift in UK VCT tax policy.

Researchers at Kanazawa University have developed engineered nanoparticles that can reprogram rogue immune cells, offering a targeted therapy for autoimmune diseases.

With backing from AstraZeneca and Pfizer, Beijing’s Syneron Bio is using its AI-driven platform to develop novel drugs for cancer and chronic illness.

Tech billionaire and commercial astronaut Jared Isaacman is the new NASA chief. Can his entrepreneurial vision and private space experience reshape the agency?

In a major move for the AI infrastructure race, TeraWulf and Fluidstack secure massive project financing for a 168 MW Texas facility, backed by Google.

A new AI accelerator promises to cut the complex Adobe Experience Platform migration from weeks to days, reshaping digital transformation timelines.

In a fierce biotech talent war, Senti Bio's new equity grant for a key hire signals a strategic push for its gene therapy pipeline amid market volatility.